[HTML][HTML] Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

…, JJ Buggy, BY Chang, DM Beaupre… - … England Journal of …, 2013 - Mass Medical Soc
Background Bruton's tyrosine kinase (BTK) is a mediator of the B-cell–receptor signaling
pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK …

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

…, F Clow, B Munneke, D Moussa, DM Beaupre… - Nature medicine, 2015 - nature.com
The two major subtypes of diffuse large B cell lymphoma (DLBCL)—activated B cell–like (ABC)
and germinal center B cell–like (GCB)—arise by distinct mechanisms, with ABC …

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

…, L Baher, M Cheng, D Lee, DM Beaupre… - Blood, The Journal …, 2015 - ashpublications.org
Ibrutinib, an oral inhibitor of Bruton tyrosine kinase, is approved for patients with mantle cell
lymphoma (MCL) who have received one prior therapy. We report the updated safety and …

Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma

…, B Munneke, I Dimery, DM Beaupre… - Blood, The Journal …, 2017 - ashpublications.org
Marginal zone lymphoma (MZL) is a heterogeneous B-cell malignancy for which no
standard treatment exists. MZL is frequently linked to chronic infection, which may induce B-cell …

RAS and Leukemia: From Basic Mechanisms to Gene-Directed Therapy

DM Beaupre, R Kurzrock - Journal of clinical oncology, 1999 - ascopubs.org
PURPOSE AND DESIGN: The purpose of this review is to provide an overview of the literature
linking Ras signaling pathways and leukemia and to discuss the biologic and potential …

Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor–neutralizing monoclonal antibody, in a first-in-human study of …

…, SG Eckhardt, A Anderson, DM Beaupre… - Clinical Cancer …, 2010 - AACR
Purpose: The aims were to assess the safety, pharmacokinetics, maximum tolerated dose,
and antitumor activity of AMG 102, a fully human hepatocyte growth factor/scatter factor (HGF/…

[PDF][PDF] Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia

…, CC Mak, M Jarvis, C Bossard, DM Beaupre… - Cancer Cell, 2023 - cell.com
Therapy resistance is a major challenge in the treatment of cancer. Here, we performed
CRISPR-Cas9 screens across a broad range of therapies used in acute myeloid leukemia to …

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL

…, E Kingsley, J Ping, DM Beaupre… - Blood, The Journal …, 2019 - ashpublications.org
The outcome of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) is
poor, particularly in patients ineligible for stem cell transplantation or who fail induction …

Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open‐label studies

…, F Clow, JD Goldberg, D Beaupre… - British journal of …, 2017 - Wiley Online Library
Ibrutinib is highly active in treating mantle cell lymphoma ( MCL ), an aggressive B‐cell
lymphoma. We pooled data from three ibrutinib studies to explore the impact of baseline patient …

Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors

…, A Ang, AB Halim, RA Beckman, D Beaupre… - Clinical Cancer …, 2013 - AACR
Purpose: HER3 is a key dimerization partner for other HER family members, and its
expression is associated with poor prognosis. This first-in-human study of U3-1287 (NCT00730470), …